Pomerantz says it filed Regeneron securities class action over Fianlimab disclosures
Pomerantz LLP says it filed a securities class action against Regeneron Pharmaceuticals over disclosures tied to the Fianlimab-Libtayo study and a Phase 3 Fianlimab trial.
Pomerantz LLP says it has filed a securities class action against Regeneron Pharmaceuticals Inc. over disclosures tied to the company’s Fianlimab-Libtayo study and a Phase 3 Fianlimab trial. The investor notice says shareholders who bought Regeneron securities during the class period have until Sept. 14, 2026, to ask a court to appoint them lead plaintiff.
Pomerantz says the case relates to two company announcements it says pushed Regeneron’s stock lower. In the notice, the firm says investors may have suffered losses after those disclosures and that the lawsuit concerns whether Regeneron and certain officers or directors engaged in securities fraud or other unlawful business practices.
According to the notice, Regeneron said on April 29, 2026, during its first-quarter earnings call, that the Phase III Fianlimab-Libtayo study had been altered to expand the number of patients eligible for analysis of progression-free survival. Pomerantz says the stock fell $45.41, or 6.21%, to $686.36 after that disclosure.
The notice also says Regeneron issued a press release on May 15, 2026, saying the Phase 3 Fianlimab trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival, or PFS. Pomerantz says the stock fell $68.57, or 9.82%, to $629.68 on May 16, 2026.
The case centers on how Regeneron described the status and results of the Fianlimab program, which is part of the company’s oncology work. The notice does not include Regeneron’s response to the allegations. It identifies the company as Regeneron Pharmaceuticals Inc., NASDAQ: REGN.
Pomerantz’s notice says a copy of the complaint is available at pomerantzlaw.com. It also provides contact information for Danielle Peyton at the firm. Because the alert is a law-firm investor notice, the underlying allegations remain claims in litigation unless and until a court rules on them.
Investors who believe they were affected by the disclosures can seek to be appointed lead plaintiff by Sept. 14, 2026, according to the notice.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()